Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer

Cisplatin-based neoadjuvant chemotherapy (NAC) is recommended prior to radical cystectomy for muscle-invasive bladder cancer (MIBC) patients. Despite a 5–10% survival benefit, some patients do not respond and experience substantial toxicity and delay in surgery. To date, there are no clinically appr...

Full description

Bibliographic Details
Main Authors: Anastasia C. Hepburn, Nicola Lazzarini, Rajan Veeratterapillay, Laura Wilson, Jaume Bacardit, Rakesh Heer
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
muscle invasive bladder cancer
neoadjuvant chemotherapy
cisplatin
biomarker
machine learning
CNGB1
Online Access:https://www.mdpi.com/2072-6694/13/15/3903

Internet

https://www.mdpi.com/2072-6694/13/15/3903

Similar Items